Blackford, a leading imaging AI platform and solutions provider, has partnered with Ligence Medical AI Solutions to bring the power of AI-enabled echocardiography analysis to the Blackford Platform. This collaboration aims to transform cardiology by allowing clinicians to analyze transthoracic echocardiography with the assistance of AI.
Ligence Heart, a web-based echocardiography analysis suite, offers fully integrated and automatic analysis of echocardiographic images just moments after they are taken. By mimicking the steps performed by a cardiologist and sonographer, Ligence Heart significantly reduces the time required for each procedure. The AI solution provides accurate measurements and offers standardization in reporting, leading to enhanced efficiency and workflow optimization for clinicians.
CEO of Blackford, Ben Panter, emphasizes the commitment to broaden clinical and operational AI use cases. This partnership with Ligence expands Blackford’s cardiology portfolio and enables healthcare organizations to leverage the benefits of the Ligence Heart AI solution.
The Ligence Heart AI solution not only speeds up the evaluation time for certain measurements by at least 30%, but it also provides fully automated morphometric measurements, continuous wave analysis, pulsed wave analysis, tissue Doppler analysis, and easy integration with PACS. The accuracy of the AI solution is non-inferior to a cardiologist at up to 94%. Additionally, it generates standardized reports and automates the generation of echocardiography reports.
Dovydas Matuliauskas, MD, co-founder of Ligence and Business Development Manager, highlights the seamless evaluation and implementation of new AI tools through the Blackford platform. This partnership will broaden customer access to Ligence Heart, revolutionizing echocardiography analysis and further reducing procedure time.
Ligence Heart is CE certified in the EU, and the company is currently awaiting FDA clearance in the US, which will allow clinicians worldwide to benefit from this innovative AI solution.
Blackford and Ligence’s collaboration demonstrates their commitment to advancing cardiology through AI-enabled analysis. By combining Blackford’s strategic imaging AI platform with Ligence’s state-of-the-art echocardiography AI solution, healthcare organizations can unlock the full potential of AI and improve patient outcomes.
For more information about Ligence Heart and its capabilities, please visit www.ligence.io. To learn more about Blackford’s tailored approach to AI solutions, visit www.blackfordanalysis.com. Stay updated on their latest news and developments by following them on Twitter and LinkedIn.
About Ligence:
Ligence is a medical device company with expertise in medical ultrasound diagnostics. Their mission is to democratize 2D transthoracic echocardiography (2D TEE) by providing fully automated analysis and reporting solutions. Founded by a team of medical practitioners, Ligence aims to reduce manual work and standardize reporting in echocardiography.
About Blackford:
Blackford is a pioneering company in the radiology AI space, boasting over a decade of experience in collaboration with leading hospitals and groundbreaking technology providers. They serve as a strategic AI partner, offering hospitals access to a core platform, tailored services, and a wide range of applications. With Bayer’s recent arms-length acquisition of Blackford, customers and partners can rest assured of long-term support and security for their AI strategies.
